All VCT, EIS, SEIS, and Business Relief qualifying investments are high risk and are not suitable for most clients. They are illiquid investments and Investors’ capital is at risk.

Boundary Capital announces latest investments


Boundary Capital has announced its latest investments in Toxibact, a disruptive technology which has the potential to kill a wide range of microorganisms and AB-Polyblok, a revolutionary technology which has the potential to treat, and potentially partially reverse, the effects of Alzheimer’s Disease.